Gregg Williams Acquires 1,587,301 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,587,301 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was purchased at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the transaction, the director owned 36,119,086 shares of the company’s stock, valued at approximately $45,510,048.36. This represents a 4.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Gregg Williams also recently made the following trade(s):

• On Friday, May 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The stock was purchased at an average price of $1.26 per share, with a total value of $1,999,999.26.
• On Wednesday, April 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The stock was purchased at an average price of $1.26 per share, with a total value of $1,999,999.26.

Vivani Medical Stock Down 1.7%

Shares of VANI stock opened at $1.15 on Thursday. Vivani Medical, Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $1.92. The stock has a market cap of $99.18 million, a P/E ratio of -2.87 and a beta of 2.31. The business has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.25.

Vivani Medical (NASDAQ:VANI) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). On average, sell-side analysts anticipate that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright dropped their price objective on Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, June 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.50.

Institutional Trading of Vivani Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL purchased a new stake in Vivani Medical in the 4th quarter valued at about $1,127,000. Geode Capital Management LLC grew its holdings in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after buying an additional 105,398 shares during the period. State Street Corp grew its holdings in Vivani Medical by 12.5% in the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after buying an additional 16,070 shares during the period. Marshall Wace LLP purchased a new stake in Vivani Medical in the 4th quarter valued at about $174,000. Finally, Renaissance Technologies LLC grew its holdings in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after buying an additional 53,127 shares during the period. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.